Status:
COMPLETED
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS
Lead Sponsor:
Mapi Pharma Ltd.
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
* This is a phase IIa study in which GA Depot 80 or 40mg is administered as an IM injection to subjects with RRMS at 4 week intervals for 52 weeks of treatment. * The purpose of the study is to assess...
Detailed Description
* 25 Subjects with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who are treated with daily or thrice weekly subcutaneous injections of 20 mg or 40 mg respectively of GA (Copaxone®) dur...
Eligibility Criteria
Inclusion
- Male or female subjects with a diagnosis of RRMS.
- Diagnosis of multiple sclerosis (MS) consistent with the McDonald Criteria (revisions of 2010).
- Treatment with 20 mg or 40 mg of GA (Copaxone®) during the previous 12 months with ongoing treatment at the Screening Visit.
- Normal renal function.
- Normal liver function.
- Normal hemoglobin concentration.
- Absence of any clinically significant medical, psychiatric or laboratory abnormalities.
- Ability to provide written informed consent.
Exclusion
- Any relevant medical, surgical, or psychiatric condition, laboratory value, or concomitant medication which, in the opinion of the investigator, makes the subject unsuitable for study entry or potentially unable to complete all aspects of the study.
- Concomitant Autoimmune disease.
- Severe anemia (hemoglobin \< 10 g/dL).
- Abnormal renal function (serum creatinine \> 1.5xULN).
- Abnormal liver function (transaminases \>2xULN).
- Pregnant or breast-feeding women.
- Women capable of child bearing must have a negative urine pregnancy test at screening visit and use an adequate contraceptive method throughout the study. Women who are surgically sterile (hysterectomy or tubal ligation) or whose last menstruation was 12 months or more prior to the Screening Visit are considered to be of non-child-bearing potential. Acceptable forms of contraception include oral, implanted, or injected contraceptives; intrauterine devices in place for at least 3 months; estrogen patch; and adequate barrier methods in conjunction with spermicide. Abstinence is considered an acceptable contraceptive regimen.
- History of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study drug, e.g. GA, polylactic-co-glycolic acid (PLGA), polyvinyl alcohol (PVA).
- Known or suspected history of drug or alcohol abuse.
- Positive test for HIV, hepatitis, venereal disease research laboratory test (VDRL), or tuberculosis.
- Participation in an investigational drug study within 30 days prior to start of this study.
- Active malignant disease of any kind. However, a patient, who has had a malignant disease in the past, was treated and is currently disease - free for at least 5 years, may be considered to be enrolled in the study. In this case the sponsor medical expert approval is required.
- Treatment with any kind of steroids during the last 30 days.
- Confirmed relapse during the last 30 days.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 20 2024
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT02212886
Start Date
October 1 2014
End Date
November 20 2024
Last Update
December 3 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Barzilai Medical Center
Ashkelon, Israel
2
Rambam Medical Center
Haifa, Israel
3
TASMC
Tel Aviv, Israel